Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.


Related Content

NICE’s Nod To Arzerra In CLL A Prelude To Rivalry With Gazyvaro, MabThera
CLL Market Snapshot: Seismic Changes Rock The Treatment Landscape
Payers Come To Terms With Long-Term Coverage Of New CLL Drugs
Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution
Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts